Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Andrea Németh has successfully applied to the John Fell Fund to establish the Oxford Neurodevelopment Consortium (OxNDC).

Neurodevelopmental disorders include intellectual disability, autism, cerebellar ataxias, epilepsies, and many others. Mental health and neurodegenerative disorders may also have developmental antecedents. They are lifelong conditions with few disease-modifying treatments.  

Large-­scale DNA sequencing studies are unravelling the genetic basis of some of these conditions and this is providing exciting new opportunities to study these conditions, especially when combined with other clinical and basic sciences.

The aim of the OxNDC is to bring together all interested clinical and basic scientists working on neurodevelopmental disorders in Oxford. This will include those working in imaging and neuropathology, and those using cellular or animal models as well those using patient cohorts for genetic or other analysis.

The consortium will strengthen existing collaborations; form new collaborations; and share ideas, resources, materials and protocols. It will create a critical mass of clinicians and scientists with a new momentum capable of securing competitive funding, breaking new ground, and identifying potential therapeutic targets.

Get involved

The inaugural meeting of the OxNDC is planned for March. Those interested, including anyone who would like to present their work, can contact andrea.nemeth@ndcn.ox.ac.uk for more information.

Similar stories

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Royal Academy of Engineering Research Fellowship

Dr Rezvan Farahibozorg has received one of 17 Royal Academy of Engineering Research Fellowships for 2022.

Three New Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.

Insights into the molecular pathways of progressive multiple sclerosis

Text by Ian Fyfe for 'Nature Reviews Neurology'